Cannabis Law Report

JUNE 11, 2019

At the time of trial, Murphy was using 2-5 grams/day of cannabis oil, “which he testified does not contain tetrahydrocannabinol (THC), the hallucinogenic component of cannabis but does contain cannabidiol (CBD), which does not have hallucinogenic effects.” Robichaud , 2007 NBQB 50. ” 40. ” 42. Footnotes.

Chronic Pain 45

Chronic Pain Cannabis History Treatment 45

Cannabis Law Report

NOVEMBER 24, 2021

The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). The TGA regulations permit applications for most cannabis products but nevertheless distinguish between cannabis products based on CBD and THC. 2016 ; Sznitman et al.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 29, 2019

Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.

Safety 45

Safety CBD Clinical Trials Treatment 45

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

Pharmaceutical 73

Pharmaceutical Extraction CBD Epilepsy 73